Kura Oncology(US:KURA) ZACKS·2025-08-07 23:16Core Viewpoint - Kura Oncology reported a significant quarterly loss of $0.75 per share, which was much worse than the Zacks Consensus Estimate of $0.15, indicating a negative earnings surprise of -600.00% [1] Financial Performance - The company posted revenues of $15.29 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 89.23%, compared to zero revenues a year ago [2] - Kura Oncology has surpassed consensus EPS estimates two times over the last four quarters [2] Stock Performance - Kura Oncology shares have declined approximately 30.8% since the beginning of the year, while the S&P 500 has gained 7.9% [3] Future Outlook - The company's earnings outlook will be crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.56 on revenues of $59.35 million, and for the current fiscal year, it is -$1.31 on revenues of $229.86 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Kura Oncology belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable industry outlook [8]